Cipro, as available from The Generic Source, is a drug used for the treatment of infections caused by certain strains of microorganisms. Adults typically use it for urinary tract infections.
Cipro, as available from The Generic Source, is a drug used for the treatment of infections caused by certain strains of microorganisms. Adults typically use it for urinary tract infections. The result of such infections are those of enterobacter cloacae, serratia marcescens, proteus mirabilis, Escherichia coli, klebsiella pneumoniae, providencia rettgeri, Escherichia coli, staphylococcus saprophyticus, morganella morganii, citrobacter diversus, citrobacter freundii, pseudomonas aeruginosa, methicillin-susceptible staphylococcus epidermidis, staphylococcus saprophyticus, or enterococcus faecalis.
Cipro, although not recommended through clinical trials for streptococcus pneumoniea, or standard pneumonia, is good for treating lower respiratory infections caused by Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae. Cipro is also used for Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis.
Lung, skin, and skin structure infections find Cipro a good treatment including acute sinusitis, penicillin-susceptible Streptococcus pneumonia, Haemophilus influenzae, Moraxella catarrhalis, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, or Streptococcus pyogenes.
Other main uses of Cipro include infectious diarrhea, acute sinusitis, bone and joint infections caused by Escherichia coli (enterotoxigenic strains), campylobacter jejuni, shigella boydii shigella dysenteriae, shigella flexneri, enterobacter cloacae, serratia marcescens, pseudomonas aeruginosa, escherichia coli, pseudomonas aeruginosa, proteus mirabilis, klebsiella pneumoniae, or bacteroides fragilis.
In cases where anaerobic organisms are suspected as the source or as an aggravation to the infection, the appropriate additional therapy should be administered. The patient should have appropriate susceptibility and culture tests made before Cipro is recommended as the appropriate treatment. If the patient is susceptible to ciprofloxacin, the use of Cipro may be started before the results of other testing is complete. If it is discovered that any of the infections found in the tests are known to be resistant to Cipro, the drug is not recommended.
Cipro tablets and oral suspension should be administered orally to adults as described in the dosage guidelines contained in the packaging. Generally, dosage must take into consideration severity and nature of the infection, status of renal function and hepatic function, the susceptibility of the causative organism, and the integrity of the patient's host-defense mechanisms. The length of the treatment depends on the severity of the infection, however, the usual duration last 7 to 14 days, unless severe symptoms appear or complications suggest a more prolonged therapy.
